Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05570305 · ClinicalTrials.gov registry record · Phase 2
Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria
A Phase 2 study, sponsored by University Medical Center Groningen.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT05570305: Completed Phase 2 study, sponsored by University Medical Center Groningen.
NCT05570305 is a Phase 2 study that has completed, run by University Medical Center Groningen. The registered enrollment target is 42 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05570305, a Phase 2 study, has completed, sponsored by University Medical Center Groningen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
The aim of this study is to test the hypothesis that the effects on albuminuria of combination treatment with the endothelin receptor antagonist zibotentan and SGLT2i dapagliflozin are complimentary and additive while the fluid retaining effects of zibotentan can be mitigated by dapagliflozin.
Primary Outcome
The change in albuminuria as expressed the percentage change of the log-transformed albumin:creatinine ratio in mg/gram. The log-transformation is because of the skewed distribution.
Interventions
- DRUG Placebo
- DRUG Dapagliflozin
- DRUG Zibotentan
- DRUG Dapagliflozin and Zibotentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2022-10-06 |
| Est. Completion | 2025-03-05 |
| Phase | Phase 2 |
What the finished NCT05570305 record still lists
NCT05570305 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT05570305 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05570305 about?
NCT05570305 is a clinical study titled "Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria". The aim of this study is to test the hypothesis that the effects on albuminuria of combination treatment with the endothelin receptor antagonist zibotentan and SGLT2i dapagliflozin are complimentary and additive while the fluid retaining effects of zibotentan can be mitigated by dapagliflozin.
What is the current status of trial NCT05570305?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2022-10-06. Estimated completion is 2025-03-05.
What interventions are being tested in trial NCT05570305?
The interventions under investigation include: Placebo (DRUG), Dapagliflozin (DRUG), Zibotentan (DRUG), Dapagliflozin and Zibotentan (DRUG).
Who is sponsoring clinical trial NCT05570305?
This trial is sponsored by University Medical Center Groningen, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05570305's enrollment target sits among peer trials
42 1339th of 2000 higher than 649 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI